新冠肺炎疫苗研究倫理探討與公眾信任之建立

The ethics of COVID-19 vaccine research and establishment of public trust

陳妤嘉(Yu-Chia Chen)

新冠肺炎 ； 緊急使用授權 ； 可問責性 ； 公眾信任 ； 公眾參與 ； COVID-19 ； Emergency Use Authorization (EUA) ； accountability ； public trust ； public engagement

應用倫理評論

71期（2021 / 10 / 01）

137 - 160

繁體中文

新冠肺炎疫情肆虐，為全球公共衛生及社會構成極大威脅。瞬息萬變之疫情，為疫苗之研發與核准帶來莫大挑戰。本文將探討疫苗研發技術與科學之不確定性及因加速疫苗研發之時程所衍發之倫理議題，並以國產高端新冠肺炎疫苗通過緊急使用授權所引發之爭議作為反思，以歐妮爾對於信任觀點之討論為核心對照國際研究成果與實務經驗，呼籲政府相關部門重視可問責性，廣納專家意見凝聚共識，落實公眾溝通並促進公眾參與，以重建信任。

The spread of the COVID-19 poses a significant threat to global public health and society. The rapidly changing epidemic has brought significant challenges to vaccine research and approval. This article will discuss the uncertainty of vaccine science and manufacturing technology, and the ethical issues arising from acceleration of the schedule of development and approval. This article also reflects the controversy caused by the emergency use authorization of the domestically developed COVID-19 vaccine-Medigen (MVC-COV1901), taking Onora O'Neill's view on trust research as the main point of discussion and compare the results of international research and actual cases. We call on government departments to pay attention to accountability, gathers expert opinions to build consensus, implement public communication, and promote public engagement to rebuild trust.

1. Blanchard, Jaymie-Lynn,Johnson, Caitlin,McIntyre, Margaret,Crowcroft, Natasha. S,McLellan, Andrea(2020).A pre and post intervention study measuring the effect of interactive education on adolescent perceptions of vaccines, vaccine safety and disease risk.Journal of Public Health,42(3),e272-e277.
2. Bolsen, Toby,Druckman, James N.(2015).Counteracting the Politicization of Science.Journal of Communication,65(5),745-769.
3. Dawson, Angus(2020).Pandemic vaccine trials: expedite, but don’t rush.Research Ethics,16(3-4),1-12.
4. Editorial(2020).COVID vaccines: the world’s medical regulators need access to open data.Nature,588,195.
5. FDA, 2021, “The Path for a COVID-19 Vaccine from Research to Emergency Use Authorization,” FDA, URL=https://www.fda.gov/media/143890/download（2021/09/05 瀏覽）.
6. Forman, Rebecca,Shah, Soleil,Jeurissen, Patrick,Jite, Mark,Mossialos, Elias(2021).COVID-19 vaccine challenges: What have we learned so far and what remains to be done?.Health Policy,125,553-567.
7. Harris, Phil,Moss, Danny(2021).Public affairs and communicating coronavirus vaccine risk: The role of government in maintaining public trust.Journal of Public Affairs,21(2),e2693.
8. Kreps, S. E.,Kriner, D. L.(2020).Model uncertainty, political contestation, and public trust in science: Evidence from the COVID-19 pandemic.Science advances,6(43),eabd4563.
9. Lazarus, Jeffrey V.,Ratzan, Scott C.,Palayew, Adam,Gostin, Lawrence O.,Larson, Heidi J.(2021).A global survey of potential acceptance of a COVID-19 vaccine.Nature medicine,27(2),225-228.
10. O’Neill, Onora(2018).Linking Trust to Trustworthiness.International Journal of Philosophical Studies,26(2),293-300.
11. O’Neill, Onora, 2017, “Trust, Trustworthiness And Transparency,” The British Academy, URL=https://www.thebritishacademy.ac.uk/documents/2563/Future-of-the-corporation-Trust-trustworthiness-transparency.pdf（2021/09/05 瀏覽）。
12. O’Neill, Onora(2002).Autonomy and Trust in bioethics.Cambridge:Cambridge University Press.
13. O’Neill, Onora(2004).Accountability, trust and informed consent in medical practice and research.Clinical medicine,4(3),269-276.
14. Petersen, Michael Bang,Bor, Alexander,Jørgensen, Frederik,Lindholt, Marie Fly(2021).Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust.Proceedings of the National Academy of Sciences,118(29),e2024597118.
15. 王竣鋒(2021)。美國 FDA 於 2021 年 2 月更新「預防 COVID-19疫苗之緊急使用授權」指引。當代醫藥法規月刊，127，23-24。
16. 林育瑄，2021，〈以免疫橋接方式審 EUA 臺灣首創？陳時中：WHO 有討論〉，中央通訊社網站，URL=https://www.cna.com.tw/news/aipl/202106110115.aspx（2021/09/10 瀏覽）。
17. 邱鈺婷(2020)。歐盟 EMA 於 2020 年 11 月發表「COVID-19 疫苗相關之安全監視計畫及風險管理計畫」指引。當代醫藥法規月刊，122，34-35。
18. 莫奈河， 2021 ，〈誰讓戰略產業 ── 高端疫苗成為「一代拳王」？〉，新新聞，URL=https://new7.storm.mg/article/3915979（2021/09/ 10 瀏覽）。
19. 陳毓茹(2021)。歐盟 EMA 於 2020 年 11 月發表「對於 COVID-19疫苗核准的考量」觀點討論。當代醫藥法規月刊，124，41-42。
20. 陳潔，2021，〈疫苗進行式：COVID-19 全球疫苗接種即時追蹤〉，報導者 The Reporter，URL=https://www.twreporter.org/a/covid-19-vaccinations-across-the-world（2021/09/05 瀏覽）。
21. 陳潔、嚴文廷、楊惠君，2021，〈首支取得 EUA 的國產高端疫苗，防疫角色如何定位？保護力監測與國際接軌考驗在哪？〉，報導者 The Reporter，URL=https://www.twreporter.org/a/covid-19-medigen-vaccines-eua （2021/08/31 瀏覽）。
22. 黃天如，2021，〈審查委員條件全淪建議！高端 EUA 標準全球首創審查委員條件全淪為建議 〉， 新新聞 ， URL=https://new7.storm.mg/article/3857590（2021/09/05 瀏覽）。
23. 謝柏宏，2020，〈本土新冠疫苗臨床標準變嚴〉，聯合新聞網，URL=https://udn.com/news/story/7241/4966106（2021/09/10 瀏覽）。
24. 醫藥品查驗中心，2021，〈國產 COVID-19 疫苗臨床研發及試驗設計之法規科學考量〉，醫藥品查驗中心公告，URL=https://www.cde.org.tw/news/news_more？id=256（2021/09/10 瀏覽）。